The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index, and 3 are not checked yet.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Open accessAbstract
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. RESULTS: At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group. CONCLUSIONS: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01206062.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Systolic Blood Pressure Intervention Trial, 261 patients at high cardiovascular risk who were already using antihypertensive drugs targeting a systolic BP of 120 mmHg had an approximately twofold risk of syncope vs. the control group targeting a systolic BP of 140 mmHg.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [261]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results have been interpreted to be generally consistent between the two trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (38,40).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular benefit of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The primary composite outcome of MI, coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (38).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The results of BPROAD and ESPRIT are supported by the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
In the citing paper
“in which there was a notable 25% relative/0.5% absolute reduced risk per year of cardiovascular morbidity and mortality with intensive (<120 mm Hg) as compared with standard (<140 mm Hg) systolic blood pressure control in patients with hypertension and high cardiovascular risk.71”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [71]
In the citing paper
“This graded approach is based on evidence from multiple meta-analyses and individual RCTs, which show a consistent and graded reduction in CVD risk in response to reductions in TC and LDL-C levels. 61-71”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“These trials are consistent in showing that the higher the initial LDL-C level, the greater the absolute reduction in risk, while the relative risk reduction remains constant at any given baseline LDL-C level.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“The primary composite outcome of myocardial infarction (MI), coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a target systolic blood pressure of < 120 mmHg decreases cardiovascular event rates by 25% in high-risk patients, although people with diabetes were excluded from this trial (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Of note, the ACCORD BP and SPRINT trials targeted a similar systolic blood pressure < 120 mmHg, but in contrast to SPRINT, the primary composite cardiovascular end point was nonsigni fi cantly reduced in ACCORD BP.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The achieved systolic blood pressures in the trial were 121 mmHg and 136 mmHg in the intensive versus standard treatment group, respectively.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular bene fi t of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The results have been interpreted to be generally consistent between both trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Global burden of hypertension: analysis of worldwide data
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17741-1 · Cited by 8,698
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Self-citationHeart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Flagged first, then by citations
Research works printed but not linked: 3
- 10.1016/s0140-6736(05)70151-3 · DOI
- Franklin SS, 1999, Pathol Biol (Paris), 47, 594
- Nwankwo T, 2013, NCHS Data Brief, 133, 1
Cited by
Sorted by citations
Items 401–500 of 1,036
Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease
Chebib, F. T., & Torres, V. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03960318 · Cited by 128
2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Budzynski, A. Z., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., Dziedzic, T., Franek, E., et al. (2019) · Clinical Diabetology · doi:10.5603/dk.2019.0001 · Cited by 128
Derington, C. G., King, J. B., Herrick, J. S., Shimbo, D., Kronish, I. M., Saseen, J. J., Muntner, P., Moran, A. E., & Bress, A. P. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14360 · Cited by 128
Michos, E. D., Reddy, T. K., Gulati, M., Brewer, L. C., Bond, R. M., Velarde, G., Bailey, A. L., Echols, M. R., Nasser, S. A., Bays, H. E., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100250 · Cited by 128
Sex differences in neuroinflammation and neuroprotection in ischemic stroke
Spychala, M. S., Honarpisheh, P., & McCullough, L. D. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23962 · Cited by 127
Shared Decision-Making and Patient Empowerment in Preventive Cardiology
Kambhampati, S., Ashvetiya, T., Stone, N. J., Blumenthal, R. S., & Martin, S. S. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0729-6 · Cited by 127
Karmali, K. N., Lloyd‐Jones, D. M., van der Leeuw, J., Goff, D. C., Yusuf, S., Zanchetti, A., Glasziou, P., Jackson, R., Woodward, M., Rodgers, A., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002538 · Cited by 127
Hypertension in Cancer Patients and Survivors
Cohen, J. B., Geara, A. S., Hogan, J. J., & Townsend, R. R. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.11.009 · Cited by 127
Segar, M. W., Jaeger, B. C., Patel, K. V., Nambi, V., Ndumele, C. E., Correa, A., Butler, J., Chandra, A., Ayers, C. R., Rao, S. G., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.053134 · Cited by 126
Jordan, J., Kurschat, C. E., & Reuter, H. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0557 · Cited by 126
Clinical management of the uraemic syndrome in chronic kidney disease
Vanholder, R., Fouque, D. P., Glorieux, G., Heine, G. H., Kanbay, M., Mallamaci, F., Massy, Z. A., Ortíz, A., Rossignol, P., Więcek, A., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00033-4 · Cited by 125
Indian guidelines on hypertension-IV (2019)
Shah, S. N., Munjal, Y. P., Kamath, S. A., Wander, G. S., Mehta, N., Mukherjee, S., Kirpalani, A. L., Gupta, P., Shah, H., Rohatgi, R., et al. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0349-x · Cited by 125
Vischer, A. S., & Burkard, T. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_49 · Cited by 124
Mahfoud, F., Schmieder, R. E., Azizi, M., Pathak, A., Sievert, H., Tsioufis, C. P., Zeller, T., Bertog, S. C., Blankestijn, P. J., Böhm, M., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx215 · Cited by 124
Treatment of hypertension: The ESH/ESC guidelines recommendations
Cuspidi, C., Tadić, M., Grassi, G. M., & Mancia, G. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.10.003 · Cited by 124
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Cifu, A. S., & Davis, A. M. (2017) · JAMA · doi:10.1001/jama.2017.18706 · Cited by 124
Li, X., Li, T., Chen, J., Xie, Y., An, X., Lv, Y., & Lin, A. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16214058 · Cited by 124
Diagnosis and Management of Stable Angina
Joshi, P. H., & de Lemos, J. A. (2021) · JAMA · doi:10.1001/jama.2021.1527 · Cited by 124
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Laurent, S., Châtellier, G., Azizi, M., Calvet, D., Choukroun, G. J., Danchin, N., Delsart, P., Girerd, X. J., Gosse, P., Khettab, H., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17579 · Cited by 122
Beddhu, S., Rocco, M. V., Toto, R. D., Craven, T. E., Greene, T., Bhatt, U. Y., Cheung, A. K., Cohen, D. L., Freedman, B. I., Hawfield, A. T., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2966 · Cited by 120
Bress, A. P., Kramer, H., Khatib, R., Beddhu, S., Cheung, A. K., Hess, R., Bansal, V., Cao, G., Yee, J., Moran, A. E., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025322 · Cited by 119
Association of Blood Pressure Measurements With Peripheral Artery Disease Events
Itoga, N. K., Tawfik, D. S., Lee, C. K., Maruyama, S., Leeper, N. J., & Chang, T. I. (2018) · Circulation · doi:10.1161/circulationaha.118.033348 · Cited by 119
Upadhya, B., Rocco, M., Lewis, C. E., Oparil, S., Lovato, L. C., Cushman, W. C., Bates, J. T., Bello, N. A., Aurigemma, G., Fine, L. J., et al. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003613 · Cited by 118
Wu, Z., Jin, C., Vaidya, A., Jin, W., Huang, Z., Wu, S., & Gao, X. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07381 · Cited by 118
Research Needs to Improve Hypertension Treatment and Control in African Americans
Whelton, P. K., Einhorn, P. T., Muntner, P., Appel, L. J., Cushman, W. C., Roux, A. V. D., Ferdinand, K. C., Rahman, M., Taylor, H. A., Ard, J. D., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07905 · Cited by 118
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Tassell, B. W. V. (2017) · Diabetes Care · doi:10.2337/dc17-1366 · Cited by 117
Update on heart failure management and future directions
Choi, H., Park, M., & Youn, J. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.428 · Cited by 117
Niiranen, T., McCabe, E. L., Larson, M. G., Henglin, M., Lakdawala, N. K., Vasan, R. S., & Cheng, S. C. (2017) · BMJ · doi:10.1136/bmj.j1949 · Cited by 116
Liu, D., Li, X., Zhang, Y., Kwong, J. S. W., Li, L., Zhang, Y., Xu, C., Li, Q., Sun, X., Tian, H., et al. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s166893 · Cited by 116
Beddhu, S., Chertow, G. M., Greene, T., Whelton, P. K., Ambrosius, W. T., Cheung, A. K., Cutler, J. A., Fine, L. J., Boucher, R. E., Wei, G., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009326 · Cited by 116
Arvanitis, M., Qi, G., Bhatt, D. L., Post, W. S., Chatterjee, N., Battle, A. J., & McEvoy, J. W. (2020) · Circulation · doi:10.1161/circulationaha.120.049819 · Cited by 116
Time in Therapeutic Range, as a Determinant of All‐Cause Mortality in Patients With Hypertension
Doumas, M. N., Tsioufis, C. P., Fletcher, R. D., AMDUR, R. L., Faselis, C. J., & Papademetriou, V. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007131 · Cited by 115
Diabetes, hypertension, and cardiovascular disease development
Yen, F., Wei, J. C., Chiu, L., Hsu, C., & Hwu, C. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-021-03217-2 · Cited by 120
Nazarzadeh, M., Bidel, Z., Canoy, D., Copland, E., Bennett, D., Dehghan, A., Smith, G. D., Holman, R. R., Woodward, M., Gupta, A. K., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00172-3 · Cited by 115
Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study
Razo, C., Welgan, C. A., Johnson, C. O., McLaughlin, S. A., Iannucci, V. C., Rodgers, A., Wang, N., LeGrand, K. E., Sorensen, R. J. D., He, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01974-1 · Cited by 116
Diabetes and Cardiovascular Disease: an Update
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L. R., & Sowers, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1239-x · Cited by 114
Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation
Soliman, E. Z., Rahman, A. F., Zhang, Z.-M., Rodríguez, C. J., Chang, T. I., Bates, J. T., Ghazi, L., Blackshear, J. L., Chonchol, M., Fine, L. J., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14766 · Cited by 114
Handberg, E. M., Merz, C. N. B., Cooper‐DeHoff, R. M., Wei, J., Conlon, M., Lo, M. C., Boden, W. E., Frayne, S. M., Villines, T. C., Spertus, J. A., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.03.011 · Cited by 113
McCarthy, C. P., Bruno, R. M., McEvoy, J. W., & Touyz, R. M. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae084 · Cited by 113
McEvoy, J. W., Martin, S. S., Dardari, Z., Miedema, M. D., Sandfort, V., Yeboah, J., Budoff, M. J., Goff, D. C., Psaty, B. M., Post, W. S., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.025471 · Cited by 113
Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm
Ferraro, R., Latina, J. M., Alfaddagh, A., Michos, E. D., Blaha, M. J., Jones, S. R., Sharma, G. V., Trost, J. C., Boden, W. E., Weintraub, W. S., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.078 · Cited by 114
Malik, R., Georgakis, M. K., Vujković, M., Damrauer, S. M., Elliott, P., Karhunen, V., Giontella, A., Fava, C., Hellwege, J. N., Shuey, M. M., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16534 · Cited by 112
McNulty, H., Strain, J., Hughes, C., & Ward, M. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.10.002 · Cited by 111
Masoli, J. A. H., Delgado, J., Pilling, L. C., Strain, W. D., & Melzer, D. R. (2020) · Age and Ageing · doi:10.1093/ageing/afaa028 · Cited by 111
Current status of white coat hypertension: where are we?
Nuredini, G., Saunders, A., Rajkumar, C., & Okorie, M. (2020) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944720931637 · Cited by 110
Law, J. P., Pickup, L. C., Pavlović, D., Townend, J., & Ferro, C. J. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00751-4 · Cited by 111
Hypertension and frailty in older adults
Aprahamian, I., Sassaki, E., dos Santos, M. F., Izbicki, R., Pulgrossi, R. C., Biella, M. M., Borges, A. C. N., Sassaki, M. M., Torres, L., Fernandez, Í. S., et al. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.13135 · Cited by 110
Bundy, J. D., Mills, K. T., Chen, J., Li, C., Greenland, P., & He, J. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1240 · Cited by 109
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 109
Armenian, S. H., Chemaitilly, W., Chen, M. Y., Chow, E. J., Duncan, C., Jones, L. W., Pulsipher, M. A., Remaley, A. T., Rovó, A., Salooja, N., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.019 · Cited by 109
Sauna Bathing and Incident Hypertension: A Prospective Cohort Study
Zaccardi, F., Laukkanen, T., Willeit, P., Kunutsor, S. K., Kauhanen, J., & Laukkanen, J. A. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx102 · Cited by 108
Whelton, P. K., & Williams, B. (2018) · JAMA · doi:10.1001/jama.2018.16755 · Cited by 108
Ackland, G. L., Brudney, C. S., Cecconi, M., İnce, C., Irwin, M. G., Lacey, J., Pinsky, M. R., Grocott, M. P., Mythen, M. G., Edwards, M., et al. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.01.011 · Cited by 108
Alport Syndrome Classification and Management
Warady, B. A., Agarwal, R., Bangalore, S., Chapman, A. B., Levin, A., Stenvinkel, P., Toto, R. D., & Chertow, G. M. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.05.014 · Cited by 108
Frailty and cardiovascular mortality in more than 3 million US Veterans
Shrauner, W. R., Lord, E. M., Nguyen, X. T., Song, R. J., Galloway, A., GAGNON, D. R., Driver, J. A., Gaziano, J. M., Wilson, P. W. F., Djoussé, L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab850 · Cited by 108
Robinson, C., & Chanchlani, R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.02.018 · Cited by 108
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D. A., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A. M., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.02.009 · Cited by 111
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Stevens, W., Peneva, D., Li, J. Z., Liu, L. Z., Liu, G., Gao, R., & Lakdawalla, D. (2016) · BMC Health Services Research · doi:10.1186/s12913-016-1420-8 · Cited by 107
DuPont, J. J., McCurley, A., Davel, A. P., McCarthy, J., Bender, S. B., Hong, K., Yang, Y., Yoo, J., Aronovitz, M. J., Baur, W. E., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88942 · Cited by 107
Quasi-experimental causality in neuroscience and behavioural research
Marinescu, I., Lawlor, P. N., & Kording, K. P. (2018) · Nature Human Behaviour · doi:10.1038/s41562-018-0466-5 · Cited by 107
Banerjee, M., Reynolds, E. L., Andersson, H. B., & Nallamothu, B. K. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004879 · Cited by 107
Demir, Y. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13144 · Cited by 107
Moltó, A., Medina, C. L., den Bosch, F. E. V., Boonen, A. E. R. C. H., Webers, C., Dernis, E., van Gaalen, F. A., Soubrier, M., Claudepierre, P., Baillet, A. C., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219585 · Cited by 107
Murphy, D. P., Drawz, P. E., & Foley, R. N. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018100971 · Cited by 106
Multimodality Strategy for Cardiovascular Risk Assessment
de Lemos, J. A., Ayers, C. R., Levine, B. D., deFilippi, C. R., Wang, T. J., Hundley, W. G., Berry, J. D., Seliger, S. L., McGuire, D. K., Ouyang, P., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027272 · Cited by 106
Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice
Buonacera, A., Stancanelli, B., & Malatino, L. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171116151051 · Cited by 106
Chronic disease management in heart failure: focus on telemedicine and remote monitoring
Alvarez, P. A., Sianis, A., Brown, J., Ali, A., & Briasoulis, Α. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202046 · Cited by 106
Ernst, M. E., & Fravel, M. A. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac048 · Cited by 106
Amlodipine in the current management of hypertension
Wang, J., Palmer, B. F., Anderson, K. V., & Sever, P. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14709 · Cited by 106
Drawz, P. E., Agarwal, A., Dwyer, J. P., Horwitz, E., Lash, J., Lenoir, K., McWilliams, A., Oparil, S., Rahbari-Oskoui, F., Rahman, M., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.5028 · Cited by 105
Chamberlain, J. J., Johnson, E. L., Leal, S., Rhinehart, A. S., Shubrook, J. H., & Peterson, L. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0222 · Cited by 105
Trends in Blood Pressure Control among US Adults With Hypertension, 2013–2014 to 2021–2023
Hardy, S. T., Jaeger, B. C., Foti, K. E., Ghazi, L., Wozniak, G., & Muntner, P. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae141 · Cited by 105
Brazilian Guidelines of Hypertension – 2025
Brandão, A. A., Rodrigues, C. I. S., Bortolotto, L. A., Armstrong, A. D. C., Mulinari, R. A., Feitosa, A. D. M., Gomes, M. A. M., Barbosa, E. C. D., Moura-Neto, J. A., Neves, M. F., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250624 · Cited by 102
Egan, B. M., Sutherland, S. E., Rakotz, M., Yang, J., Hanlin, R. B., Davis, R. A., & Wozniak, G. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11558 · Cited by 104
Chang, T. I., Reboussin, D. M., Chertow, G. M., Cheung, A. K., Cushman, W. C., Kostis, W. J., Parati, G., Raj, D., Riessen, E., Shapiro, B., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09788 · Cited by 104
Gibson, T. M., Li, Z., Green, D. M., Armstrong, G. T., Mulrooney, D. A., Srivastava, D. K., Bhakta, N. H., Ness, K. K., Hudson, M. M., & Robison, L. L. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0510 · Cited by 104
Messas, E., Goudot, G., Halliday, A. W., Sitruk, J., Mirault, T., Khider, L., Saldmann, F., Mazzolai, L., & Aboyans, V. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa162 · Cited by 104
Masked hypertension: understanding its complexity
Franklin, S. S., O'Brien, E. T., & Staessen, J. A. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw502 · Cited by 103
Sex-Specific Epidemiology of Heart Failure Risk and Mortality in Europe
Magnussen, C., Niiranen, T., Ojeda, F., Gianfagna, F., Blankenberg, S., Vartiainen, E. A., Sans, S., Pasterkamp, G., Hughes, M., Costanzo, S., et al. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.08.008 · Cited by 103
Drury, E. R., Wu, J., Gigliotti, J. C., & Le, T. H. (2023) · Physiological Reviews · doi:10.1152/physrev.00041.2022 · Cited by 103
Borghi, C., Tubach, F., De Backer, G., Dallongeville, J., Guallar, E., Medina, J., Perk, J., Roy, C., Banegas, J. R., Rodriguez-Artalejo, F., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.05.044 · Cited by 102
On the utilization of polygenic risk scores for therapeutic targeting
Gibson, G. C. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008060 · Cited by 102
Cuffless Blood Pressure Monitoring: Promises and Challenges
Pandit, J. A., Lores, E., & Batlle, D. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03680320 · Cited by 101
Current status and therapeutic considerations of hypertension in the elderly
Lee, J., Kim, K., & Cho, M. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.196 · Cited by 101
Exercise and sport science australia position stand update on exercise and hypertension
Sharman, J. E., Smart, N. A., Coombes, J. S., & Stowasser, M. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0266-z · Cited by 101
Casey, D. E., Thomas, R. J., Bhalla, V., Commodore-Mensah, Y. Y., Heidenreich, P. A., Kolte, D. S., Muntner, P., Smith, S. C., Spertus, J. A., Windle, J. R., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000057 · Cited by 102
Gender Differences in Cardiovascular Pharmacotherapy—the Example of Hypertension: A Mini Review
Kalibala, J., Péchère-Bertschi, A., & Desmeules, J. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00564 · Cited by 101
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 109
Magkas, N., Tsioufis, C. P., Thomopoulos, C., Dilaveris, P., Georgiopoulos, G. A., Sanidas, E. A., Papademetriou, V., & Tousoulis, D. M. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13521 · Cited by 100
Normal‐tension glaucoma: Current concepts and approaches‐A review
Leung, D. Y. L., & Tham, C. C. (2022) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.14043 · Cited by 99
A Short History of Automated Office Blood Pressure – 15 Years to SPRINT
Myers, M. G. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12820 · Cited by 99
Orthostatic Hypotension in Middle-Age and Risk of Falls
Juraschek, S. P., Daya, N. R., Appel, L. J., Miller, E. R., Windham, B. G., Pompeii, L. A., Griswold, M. E., Kucharska‐Newton, A., & Selvin, E. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw108 · Cited by 99
Larsson, S. C., & Markus, H. S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180288 · Cited by 100
Limitations of hazard ratios in clinical trials
Stensrud, M. J., Aalen, J. M., Aalen, O. O., & Valberg, M. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy770 · Cited by 99
JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases
Yamagishi, M., Tamaki, N., Akasaka, T., Ikeda, T., Ueshima, K., Uemura, S., Otsuji, Y., Kihara, Y., Kimura, K., Kimura, T., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-19-1131 · Cited by 100
Lloyd‐Jones, D. M., Huffman, M. D., Karmali, K. N., Sanghavi, D. M., Wright, J. S., Pelser, C. B., Gulati, M., Masoudi, F. A., & Goff, D. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.018 · Cited by 99
Highlights of the 2018 Chinese hypertension guidelines
Liu, J. (2020) · Clinical Hypertension · doi:10.1186/s40885-020-00141-3 · Cited by 98
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2103-2116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4689591
- OpenAlex
- W3150595609
- Cited by
- 6,325
- References
- 38
- Citations by year
- 2026: 390 · 2025: 449 · 2024: 437 · 2023: 498 · 2022: 523 · 2021: 602 · 2020: 570 · 2019: 694 · 2018: 734 · 2017: 767 · 2016: 613 · 2015: 40
- FWCI
- 522.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR001427, UL1TR000073, UL1TR001064, UL1TR001085, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
- National Institute on Aging (P30AG021332)
- National Heart, Lung, and Blood Institute (HHSN268200900040C, A-HL-13-002-001, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
- National Institute of General Medical Sciences (P30GM103337)
- National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
- National Center for Advancing Translational Sciences (9U54TR000017‐06)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, cardiovascular risk, cardiovascular events, all-cause mortality, adverse events, hypotension, acute kidney injury, non-diabetic patients
- MeSH terms
- Age Factors, Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Cause of Death, Female, Goals, Humans, Hypertension, Male, Middle Aged, Risk Factors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
